Clinical trialEPhase 1Recruiting
Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer
An Exploratory Clinical Study of Safety and Efficacy of Neoantigen mRNA Vaccines in the Treatment of Patients With Resectable Pancreatic Cancer
- Outcome
- Ongoing
- Phase
- EPhase 1
- Status
- Recruiting
- Study type
- Interventional
- Start
- April 2024
- Expected end
- December 2026
- Enrollment
- 12 participants
- Sites
- 1
- Primary outcomes
- Incidence of Treatment Emergent Adverse Events (TEAEs)
- Sponsor
- Other
- Results posted
- No
- Last update
- 22 March 2024
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to evaluate the safety and efficacy of treating pancreatic cancer with surgery to remove cancerour tissue, followed by camrelizumab and a personalized cancer mRNA vaccines.
Detailed description public domain (ClinicalTrials.gov)
The first purpose of this study is to evaluate the safety of treating pancreatic cancer with surgery to remove cancerour tissue. Following with camrelizumab and a personalized Neoantigen mRNA Vaccines, and then with chemotherapy.